Anti-p53 T-cell receptor-transduced PBL(NCI)(Anti-p53 T-cell receptor-transduced PBL(NCI))

概要

基本信息

药物类型

T细胞疗法

别名-

靶点-

作用机制

细胞替代物

治疗领域

肿瘤皮肤和肌肉骨骼疾病泌尿生殖系统疾病

在研适应症-

非在研适应症

皮肤黑色素瘤肿瘤转移肾细胞癌

原研机构

National Cancer Institute

在研机构-

非在研机构

National Institutes of Health Clinical Center

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Anti-p53 T-cell receptor-transduced PBL(NCI) 相关的临床试验

NCT00704938 / Terminated临床2期IIT

Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination

RATIONALE: Gene-modified lymphocytes may stimulate the immune system in different ways and stop tumor cells from growing. High-dose aldesleukin may stimulate lymphocytes to kill tumor cells. Vaccines made from a gene modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells. Giving gene-modified lymphocytes together with high-dose aldesleukin and vaccine therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving gene-modified lymphocytes together with high-dose aldesleukin and vaccine therapy works in treating patients with progressive or recurrent metastatic cancer.

开始日期2008-06-01

申办/合作机构

National Institutes of Health Clinical Center

[+1]

100 项与 Anti-p53 T-cell receptor-transduced PBL(NCI) 相关的临床结果

登录后查看更多信息

100 项与 Anti-p53 T-cell receptor-transduced PBL(NCI) 相关的转化医学

登录后查看更多信息

100 项与 Anti-p53 T-cell receptor-transduced PBL(NCI) 相关的专利（医药）

登录后查看更多信息

100 项与 Anti-p53 T-cell receptor-transduced PBL(NCI) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
皮肤黑色素瘤	临床2期	美国	National Institutes of Health Clinical Center	2008-06-01
肿瘤转移	临床2期	美国	National Institutes of Health Clinical Center	2008-06-01
肾细胞癌	临床2期	美国	National Institutes of Health Clinical Center	2008-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00704938 (CTgov)	临床2期	皮肤黑色素瘤 \| 肿瘤转移 \| 肾细胞癌 ... 更多	3	autologous dendritic cell-adenovirus p53 vaccine+fludarabine phosphate+cyclophosphamide+Filgrastim+anti-p53 T-cell receptor-transduced peripheral blood lymphocytes+aldesleukin (Anti-p53 TCR PBL + DC + IL-2: Melanoma/RCC)	鑰鹹顧選齋顧觸鹹獵鑰(衊構艱窪鑰構製構淵範) = 鏇淵顧醖蓋艱積襯淵範廠衊艱獵憲願鬱醖築鹹 (鏇窪壓範蓋襯築醖願鹽, 壓襯廠廠醖選齋構築淵 ~ 膚壓窪淵積膚積衊淵壓) 更多	-	2012-08-14
				autologous dendritic cell-adenovirus p53 vaccine+fludarabine phosphate+cyclophosphamide+Filgrastim+anti-p53 T-cell receptor-transduced peripheral blood lymphocytes+aldesleukin (Anti-p53 TCR PBL + DC + IL-2: Other Histology)	鑰鹹顧選齋顧觸鹹獵鑰(衊構艱窪鑰構製構淵範) = 襯糧壓積壓窪窪餘築憲廠衊艱獵憲願鬱醖築鹹 (鏇窪壓範蓋襯築醖願鹽, 鏇廠餘網鹹淵艱鹹衊衊 ~ 繭鏇襯構餘網淵築築夢) 更多